Jump to ContentJump to Main Navigation
Show Summary Details
Weitere Optionen …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Wissenschaftlicher Beirat: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi


CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

Online
ISSN
1868-1891
Alle Formate und Preise
Weitere Optionen …
Band 36, Heft 2

Hefte

Impact of opioid therapy on gonadal hormones: focus on buprenorphine

Anjali Varma
  • Korrespondenzautor
  • Mental Health Clinic, Lead Psychiatrist Buprenorphine Clinic, Veterans Affairs Medical Centre, 1970 Roanoke Blvd., Salem, VA, USA, Phone: +5409822463, ext 3555, Fax: +540-855-3452
  • Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA
  • Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Roanoke, VA, USA
  • E-Mail
  • Weitere Artikel des Autors:
  • De Gruyter OnlineGoogle Scholar
/ Mamta Sapra
  • Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA
  • Memory Assessment Clinic, Chair, IRB, Veterans Affairs Medical Centre, 1970 Roanoke Blvd., Salem, VA, USA
  • Weitere Artikel des Autors:
  • De Gruyter OnlineGoogle Scholar
/ Ali Iranmanesh
  • Veterans Affairs Medical Centre, Salem, VA, USA
  • Virginia Tech Carilion School of Medicine, Roanoke, VA, USA
  • Weitere Artikel des Autors:
  • De Gruyter OnlineGoogle Scholar
Online erschienen: 17.02.2018 | DOI: https://doi.org/10.1515/hmbci-2017-0080

Abstract

Objective

The USA is in the midst of an opioid crisis. Understanding the impact of opioids and commonly used treatments for opioid dependence is essential for clinicians and researchers in order to educate and treat the nation’s growing population with opioid use disorders. As a relatively new treatment for opioid dependence, buprenorphine is gaining popularity to the extent of becoming not only a preferred approach to the maintenance of opiate addiction, but also an option for chronic pain management. The purpose of this report is to review the available evidence on the endocrine effects of buprenorphine, particularly as it relates to the hypothalamic-pituitary-gonadal (HPG) axis, which is controversial and not fully defined.

Method

We conducted a Pubmed search (2000–2017) for human studies in the English language for articles that were available as full length regarding buprenorphine, endocrinopathy, hypogonadism, bone density, opioids. Case reports were also reviewed, although prospective studies and randomized controlled trials received more weight.

Results

Opioid induced hypogonadism is well established. Most studies report that buprenorphine being a partial agonist/antagonist may not be impacting the pituitary trophic hormones as much. There are reports of sexual dysfunction in subjects maintained on buprenorphine, some without hormonal correlation. Thus with the understanding that pertinent clinical studies are limited in number, varied in methodology, mostly cross sectional, predominantly in men and small number of participants, more research in this area is warranted.

Conclusion

Based on a comprehensive review of the available literature, we conclude that despite its increasing popularity, buprenorphine has not been adequately studied in respect to its long-term effects on the hypothalamic-pituitary-adrenal (HPA) axis. There is a great need for longitudinal systematic trials to define the potential buprenorphine-induced endocrine consequences.

Keywords: buprenorphine; endocrinopathy; HPG; hypogonadism; LH; opioids; testosterone

References

  • [1]

    NSDUH Report. America’s behavioral health-changes and challenges. 2016. www.SAMHSA.GOV/DATA.

  • [2]

    Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM; Centers for Disease Control and Prevention (CDC). Controlled substance prescribing patterns – prescription behavior surveillance system, Eight States, 2013. MMWR Surveill Summ. 2015;64:1–14.CrossrefPubMedGoogle Scholar

  • [3]

    Pasternak GW. The opiate receptors 2010. 2nd ed. New York, NY, USA: Humana Press; 2010. p. 23–48.Google Scholar

  • [4]

    Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428–50.Web of SciencePubMedCrossrefGoogle Scholar

  • [5]

    Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70:S49–57.PubMedCrossrefGoogle Scholar

  • [6]

    Dunlap B, Cifu AS. Clinical management of opioid use disorder. J Am Med Assoc. 2016;316:338–9.CrossrefGoogle Scholar

  • [7]

    Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [8]

    Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150–68.PubMedCrossrefGoogle Scholar

  • [9]

    Muriel C, Failde I, Micó JA, Neira M, Sánchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther. 2005;27:451–62.CrossrefPubMedGoogle Scholar

  • [10]

    Cicero TJ, Bell RD, Wiest WG, Allison JH, Polakoski K, Robins E. Function of the male sex organs in heroin and methadone users. N Engl J Med. 1975;292:882–7.CrossrefPubMedGoogle Scholar

  • [11]

    Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.CrossrefWeb of SciencePubMedGoogle Scholar

  • [12]

    Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84.PubMedCrossrefGoogle Scholar

  • [13]

    Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25:170–5.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [14]

    Mendelson JH, Meyer RE, Ellingboe J, Mirin SM, McDougle M. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther. 1975;195:296–302.PubMedGoogle Scholar

  • [15]

    Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–22.CrossrefPubMedGoogle Scholar

  • [16]

    Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251–4.CrossrefPubMedGoogle Scholar

  • [17]

    Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90:203–6.CrossrefPubMedGoogle Scholar

  • [18]

    Al-Gommer O, George S, Haque S, MoselhyH, Saravanappa T. Sexual dysfunction in male opiate users: a comparative study of heroin, methadone and buprenorphine. Addict Disord Treat. 2007;6:137–43.CrossrefGoogle Scholar

  • [19]

    Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5:684–92.Web of ScienceCrossrefPubMedGoogle Scholar

  • [20]

    Quaglio G, Lugoboni F, Pattaro C, Melara B, Mezzelani P, Des Jarlais DC. Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug Alcohol Depend. 2008;94:12–8.Web of ScienceCrossrefPubMedGoogle Scholar

  • [21]

    Giacomuzzi SM, Khreis A, Riemer Y, Garber K, Ertl M. Buprenorphine and methadone maintenance treatment – sexual behaviour and dysfunction prevalence. Lett Drug Des Discov. 2009;6:13–13(1).CrossrefWeb of ScienceGoogle Scholar

  • [22]

    Colameco S, Coren JS, Zimmerman DJ. Buprenorphine-induced symptomatic hypogonadism in men: case reports and discussion. J Addict Med. 2008;2:147–50.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [23]

    Ramdurg S, Ambekar A, Lal R. Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence. J Sex Med. 2012;9:3198–204.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [24]

    Cioe PA, Friedmann PD, Stein MD. Erectile dysfunction in opioid users: lack of association with serum testosterone. J Addict Dis. 2010;29:455–60.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [25]

    Aloisi AM, Aurilio C, Bachiocco V, Biasi G, Fiorenzani P, Pace MC, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology. 2009;34:S162–8.PubMedCrossrefGoogle Scholar

  • [26]

    Aurilio C, Ceccarelli I, Pota V, Sansone P, Massafra C, Barbarisi M, et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. Endocr J. 2011;58:1071–8.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [27]

    Fortin JD, Bailey GM, Vilensky JA. Does opioid use for pain management warrant routine bone mass density screening in men? Pain Physician. 2008;11:539–41.PubMedGoogle Scholar

  • [28]

    Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. 2006;85:258–62.PubMedCrossrefGoogle Scholar

  • [29]

    Coluzzi F, Pergolizzi J, Raffa RB, Mattia C. The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag. 2015;11:515–23.Web of ScienceGoogle Scholar

  • [30]

    Facchinetti F, Grasso A, Petraglia F, Parrini D, Volpe A, Genazzani AR. Impaired circadian rhythmicity of beta-lipotrophin, beta-endorphin and ACTH in heroin addicts. Acta Endocrinol (Copenh). 1984;105:149–55.PubMedCrossrefGoogle Scholar

  • [31]

    Van Uum SH, Sauvé B, Fraser LA, Morley-Forster P, Paul TL, Koren G. Elevated content of cortisol in hair of patients with severe chronic pain: a novel biomarker for stress. Stress. 2008;11:483–8.Web of SciencePubMedCrossrefGoogle Scholar

  • [32]

    Camí J, Gilabert M, San L, de la Torre R. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br J Addict. 1992;87:1145–51.CrossrefPubMedGoogle Scholar

  • [33]

    Nava F, Caldiroli E, Premi S, Lucchini A. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts. J Addict Dis. 2006;25:9–16.PubMedCrossrefGoogle Scholar

  • [34]

    Pechnick RN, George R, Poland RE. The effects of the acute administration of buprenorphine hydrochloride on the release of anterior pituitary hormones in the rat: evidence for the involvement of multiple opiate receptors. Life Sci. 1985;37:1861–8.PubMedCrossrefGoogle Scholar

  • [35]

    Félix NM, Leal RO, Goy-Thollot I, Walton RS, Gil SA, Mateus LM, et al. Effects of buprenorphine in the adrenal, thyroid, and cytokine intra-operative responses in a rat model (Rattus norvegicus): a preliminary study. Iran J Basic Med Sci. 2017;20:368–379.Web of ScienceGoogle Scholar

Artikelinformationen

Erhalten: 01.12.2017

Angenommen: 12.01.2018

Online erschienen: 17.02.2018


Author Statement

Research funding: Authors state no funding involved.

Conflict of interest: Authors state no conflict of interest.

Informed consent: Informed consent is not applicable.

Ethical approval: The conducted research is not related to either human or animals use.


Quellenangabe: Hormone Molecular Biology and Clinical Investigation, Band 36, Heft 2, 20170080, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2017-0080.

Zitat exportieren

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Zitierende Artikel

Hier finden Sie eine Übersicht über alle Crossref-gelisteten Publikationen, in denen dieser Artikel zitiert wird. Um automatisch über neue Zitierungen dieses Artikels informiert zu werden, aktivieren Sie einfach oben auf dieser Seite den „E-Mail-Alert: Neu zitiert“.

[1]
Athanasios Fountas, Stan Van Uum, and Niki Karavitaki
The Lancet Diabetes & Endocrinology, 2019
[2]
Kenneth W.K. Ho
Current Opinion in Endocrine and Metabolic Research, 2019, Jahrgang 6, Seite 54

Kommentare (0)